Seonglae ChoFlu Vaccine
universal flu vaccine
Long-sought universal flu vaccine: mRNA-based candidate enters clinical trial
The phase I trial will test safety and efficacy in a small number of people.
https://arstechnica.com/health/2023/05/experimental-universal-flu-vaccine-with-an-mrna-based-design-enters-trial/
Universal flu vaccine may be available within two years, says scientist
A universal flu vaccine that protects against all strains of the virus could be available in the next two years, according to a leading scientist. An experimental vaccine based on the same mRNA technology used in the highly successful Covid jabs was found to protect mice and ferrets against severe influenza, paving the way for clinical trials in humans.
https://www.theguardian.com/society/2022/nov/25/universal-flu-vaccine-may-be-available-within-two-years-says-scientist
Scientists use mRNA technology to create a potent flu shot that could last for years
Researchers have created an mRNA-based influenza vaccine that targets four viral proteins that tend to remain the same across different strains of influenza.
https://www.inverse.com/mind-body/new-mrna-vaccine-universal-flu-shot
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older CAMBRIDGE, MA / ACCESS Newswire / June 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% (95% CI; 16.7%, 35.4%) in the overall study population. Additionally, strong rVE was observed for each influenza strain contained in the vaccine, including A/H1N1 (rVE=29.6%), A/H3N2 (rVE=22.2%), and the B/Victoria lineages (rVE=29.1%). Subgroup analyses confirmed a consistently strong rVE point
https://investors.modernatx.com/news/news-details/2025/Moderna-Announces-Positive-Phase-3-Results-for-Seasonal-Influenza-Vaccine/default.aspx